Want to see MBX full AI Analyst Report?
MBX Biosciences, Inc. (MBX) Ratios
MBX Biosciences, Inc. Ratios
MBX's free cash flow for Q2 2026 was $-23.52M. For the 2026 fiscal year, MBX's free cash flow was decreased by $-901.00K and operating cash flow was $-22.62M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 24.62 | 24.19 | 21.26 | 12.89 |
| Quick Ratio | 24.62 | 24.19 | 21.26 | 12.89 |
| Cash Ratio | 4.86 | 4.47 | 7.77 | 7.06 |
| Solvency Ratio | -5.45 | -5.56 | -0.21 | -0.30 |
| Operating Cash Flow Ratio | -5.16 | -4.95 | -8.15 | -6.74 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 365.62M | $ 256.19M | $ -73.18M | $ -43.49M |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | -0.00 | -0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | -0.00 | -0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.04 | 1.04 | -1.16 | -1.06 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -68.73 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -67.28 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.01 | 0.01 | 0.03 |
| Net Debt to EBITDA | 0.86 | 0.80 | 0.86 | 0.92 |
| Profitability Margins | ||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 88.70% | 90.80% | 92.22% | 103.87% |
| Return on Assets (ROA) | -22.58% | -23.06% | -38.68% | -57.96% |
| Return on Equity (ROE) | -23.56% | -24.05% | 44.93% | 61.34% |
| Return on Capital Employed (ROCE) | -26.53% | -26.48% | -44.00% | -60.39% |
| Return on Invested Capital (ROIC) | -26.51% | -26.47% | -43.92% | -60.19% |
| Return on Tangible Assets | -22.58% | -23.06% | -38.68% | -57.96% |
| Earnings Yield | -7.55% | -10.06% | -4.32% | -3.47% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.08 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4381.47 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 4381.47 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | -2.19 | -1.64 | -1.00 | -0.73 |
| Free Cash Flow Per Share | -2.24 | -1.66 | -1.01 | -0.74 |
| Dividend Paid and CapEx Coverage Ratio | -41.45 | -62.56 | -247.89 | -52.43 |
| Capital Expenditure Coverage Ratio | -41.45 | -62.56 | -247.89 | -52.43 |
| Operating Cash Flow Coverage Ratio | -134.14 | -319.77 | -98.70 | -50.16 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -7.11% | -9.03% | -4.26% | -3.13% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -13.25 | -9.96 | -23.13 | -28.82 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.12 | 2.39 | -10.40 | -17.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -14.06 | -11.08 | -23.46 | -31.97 |
| Price-to-Operating Cash Flow Ratio | -14.40 | -11.25 | -23.56 | -32.58 |
| Price-to-Earnings Growth (PEG) Ratio | -0.46 | -0.12 | -0.95 | 0.00 |
| Enterprise Value Multiple | -12.42 | -9.18 | -20.57 | -28.38 |
| Enterprise Value | 1.08B | 566.25M | 723.14M | 729.59M |
| EV to EBITDA | -12.42 | -9.18 | -20.57 | -28.38 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -13.15 | -10.19 | -22.52 | -30.96 |
| EV to Operating Cash Flow | -13.47 | -10.36 | -22.61 | -31.55 |
| Tangible Book Value Per Share | 10.11 | 7.71 | -2.28 | -1.34 |
| Shareholders’ Equity Per Share | 10.11 | 7.71 | -2.28 | -1.34 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.38 | -1.85 | -1.02 | -0.82 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.92 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 0.88 | 0.98 | 0.88 |
Currency in USD